Greetings!

High error reporting rate would either mean reporting culture is fantastic or plenty unsafe practices. And Lower rates could possibly be under-reporting due to punitive culture within an organisation or commendable safe practices.

So, my question is 'Is there an acceptable fine line or limit that any of your organisations have adopted to reporting culture and validate the number of reports to what's happening? If so, may I understand how this limit was defined? Is it from previous years'average data?

Does anyone have a policy/procedure for using medications off-label that they would be willing to share? We are looking for details on consent, patient education. Thank you!
Christopher Pope PharmD SGHS Pharmacy Medication Safety Committee

Hell !
A couple of questions on this- and I will share my results once people have responded.

https://www.surveymonkey.com/r/8YDKRCN

this is a three question survey- if you could please take I will post results.
It is about storage and use of POM
thanks
Laura

Good afternoon!

Hello,
My organization's clinicians have divergent opinions regarding whether or not dexmedetomidine administration should be allowed outside of critical care/ ED patient care units (e.g., intermediate care for alcohol withdrawal).

1) Do you allow use outside of critical care for alcohol withdrawal?
2) If so, What setting(s)? intermediate care only or other type of unit?
3) Please share dose restrictions that are in place and monitoring requirements.
4) Do you feel that dexmedetomidine use for this purpose qualifies as a "chemical
restraint?

ISMP states that

We continue to show consistent improvement of the measure of INR>5 after administration of warfain in our inpatient population. Has anyone had success in this area, and if so, can you share your strategies?

This is an idea and suggestion for ISMP, open for discussion. Please add your thoughts and insights.

Hi all,
Given Akorn's bankruptcy, alfentanil is no longer available after being on shortage for 6 months+.

ASHP shortage website has no alternatives.
https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-deta....

Do any of your clinic sites stock and administer Triptodur (triptorelin)? If yes, how do you maintain compliance with USP 800 in the clinic setting knowing this administration system requires manipulation and is not a closed system? I am aware that future NIOSH suggests this will be moved to table 2, but to be compliant now, what are your sites doing?